CellProthera SAS

About

CellProthera SAS is a French biotechnology company based in Mulhouse, specializing in regenerative medicine through innovative stem cell therapies. Founded in 2008, the company focuses on cardiac regeneration, particularly after acute myocardial infarction (AMI). It has developed ProtheraCytes®, a product derived from the patient's own blood that contains expanded CD34+ hematopoietic stem cells, which have angiogenic properties to aid in revascularizing ischemic lesions. The company has conducted a Phase I/IIb clinical trial and holds a total of four clinical trials, with activities reaching up to Phase 2. CellProthera employs around 30 people and generates approximately $6.9 million in revenue. Its technology platform includes a closed, automated bioprocessing system for large-scale expansion of stem cells, supporting various applications in cardiology, oncology, hematology, and more. The company also offers co-development and bioproduction services in regenerative therapies.